Shitara, K., Doi, T., Dvorkin, M., Mansoor, W., Arkenau, H., Prokharau, A., et al. (2018) Trifluridine/Tipiracil versus Placebo in Patients with Heavily Pretreated Metastatic Gastric Cancer (TAGS): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. The Lancet Oncology, 19, 1437-1448.
https://doi.org/10.1016/s1470-2045(18)30739-3

has been cited by the following article:

• TITLE: Clinicopathological Characteristics and Pathogenesis of Gastric Cancer at Different Tumor Sites

  AUTHORS: Kun Dai, Kaihai Jiang, Haige Huang

  KEYWORDS: Gastric Cancer, Different Tumor Sites, Research Progress

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.13 No.3, March 20, 2025

  ABSTRACT: Gastric cancer is one of the most common malignant tumors in the world. The incidence and mortality of gastric cancer rank high not only in China, but also in the world. In recent years, with the deepening of research on gastric cancer, it has been gradually found that gastric cancer in different locations (gastric antrum, gastric body, gastric fundus and cardia, etc.) is different in pathogenesis, clinicopathological characteristics, molecular biological characteristics, and prognosis of patients. This article reviews the differences in epidemiology, pathological and clinical characteristics, pathogenesis and the research progress of diagnosis and treatment of gastric cancer at different sites, so as to provide ideas and theoretical basis for the precise treatment of gastric cancer in China.